Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients

OBJECTIVETo determine if propylene glycol accumulates in children receiving continuous lorazepam infusion and, if accumulation occurs, to determine if it is associated with significant laboratory abnormalities. DESIGNProspective study. SETTINGA tertiary care pediatric intensive care unit. PATIENTSEl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 2002-12, Vol.30 (12), p.2752-2756
Hauptverfasser: Chicella, Michael, Jansen, Paul, Parthiban, Anitha, Marlowe, Karen F, Bencsath, F Aladar, Krueger, Kem P, Boerth, Robert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVETo determine if propylene glycol accumulates in children receiving continuous lorazepam infusion and, if accumulation occurs, to determine if it is associated with significant laboratory abnormalities. DESIGNProspective study. SETTINGA tertiary care pediatric intensive care unit. PATIENTSEleven intubated pediatric intensive care patients receiving continuous lorazepam infusion for sedation. INTERVENTIONSPropylene glycol accumulation was determined by comparing concentrations at baseline, after 48 hrs, and at end of therapy. Laboratory abnormalities were determined by comparing serum lactate and osmolar gap at baseline, after 48 hrs, and at end of therapy. Correlation between the cumulative dose of lorazepam received and the propylene glycol concentration measured at the end of therapy was determined. MEASUREMENTS AND MAIN RESULTSPatients aged 1–15 months were studied. Lorazepam infusion rates ranged from 0.1 to 0.33 mg·kg·hr and lasted 3–14 days. Propylene glycol accumulated significantly in patients receiving continuous infusion of lorazepam. The propylene glycol concentration increased during the study from 86 ± 93 μg/mL at baseline to 763 ± 660 μg/mL at the end of the study (p = .038). A statistically significant correlation between the cumulative dose of lorazepam received and propylene glycol concentration at the end of therapy was demonstrated (r = .65, p < .005). However, the propylene glycol accumulation was not associated with significant laboratory abnormalities. Neither serum lactate concentrations nor osmolar gap were significantly elevated over baseline. CONCLUSIONPropylene glycol accumulated significantly in pediatric intensive care patients receiving continuous lorazepam infusion, and propylene glycol concentration correlated with the cumulative lorazepam dose the patient received. However, significant laboratory abnormalities due to propylene glycol accumulation were not observed.
ISSN:0090-3493
1530-0293
DOI:10.1097/00003246-200212000-00021